MPN Cancer Connection

NAC May Help Ease Inflammation for MPN Patients: A phase 1/2 Clinical Trial is in progress.

Chronic inflammation is a known driver of MPN progression, and research suggests N-acetylcysteine (NAC) may help lower oxidative stress and reduce thrombotic risk.

A UC Irvine trial led by Dr. Angela Fleischman (NCT05123365) is testing the optimal NAC dose for PV, ET, and MF patients.

As always, talk to your MPN specialist before adding any supplement, especially with blood thinners.

NAC N-acetylcysteine Supplement May Benefit MPN Patients | PV Reporter N-acetylcysteine (NAC) supplement shown to have antioxidant & anti-inflammatory properties, it may reduce heart disease risk by preventing oxidative damage.

Long-term Hydroxyurea Therapy Alters Bone Marrow Megakaryocyte Morphology and Associates with Prognosis in Myeloproliferative Neoplasms (preprint)

Home Research Square is a preprint platform that makes research communication faster, fairer, and more useful.

First global approval of BESREMi® in essential thrombocythemia supports continued expansion of the PharmaEssentia MPN franchise; 👇

U.S. PDUFA date remains on track for August 30, 2026

https://www.businesswire.com/news/home/20260610421769/en/PharmaEssentia-Announces-Taiwan-Approval-of-BESREMi-for-Essential-Thrombocythemia-Marking-First-Global-Approval-in-ET

Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction

Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction Key PointsRopeg showed clinically relevant activities and manageable safety in patients with early MF.After 104 weeks, ropeg resulted in reductions in VAF